Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 92
Filter
1.
Article in Chinese | WPRIM | ID: wpr-928762

ABSTRACT

Mesenchymal stem cell (MSC) is widely used in cell therapy because of its high proliferative and multi directional differentiation potential as well as its low immunogenicity. The transplantation of MSC can help the repair of the injured organs, however, the MSC transplanted to the local organs are affected by oxidative stress and lead to premature aging or apoptosis. Heme oxygenase 1 (HO1) is a key ratelimiting enzyme in the process of heme metabolism, which has the functions of antiinflammation, antioxidation, antiapoptosis, antiaging, reducing cell damage and promoting angiogenesis. Induced high expression of HO1 in MSC could increase the ability of MSC against oxidative stress injury, delay the senescence and apoptosis of MSC, and alleviate cell injury. In this reviews, the research progress of HO1 on antioxidative stress injury of MSC.


Subject(s)
Apoptosis , Cell Differentiation , Heme Oxygenase-1/metabolism , Humans , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells , Oxidative Stress
2.
Organ Transplantation ; (6): 120-2022.
Article in Chinese | WPRIM | ID: wpr-907042

ABSTRACT

Graft-versus-host disease (GVHD) is a major cause that prevents widespread application of allogeneic hematopoietic stem cell transplantation. GVHD is a complication that can affect all systems of the body, such as skin, liver, lung and gastrointestinal tract, among which skin is the most vulnerable organ. At present, the pathogenesis of skin GVHD has not been fully elucidated, and no effective treatment has been established. Severe or extensive chronic GVHD significantly affects the quality of life of the recipients. Consequently, it is urgent to unravel the pathogenesis of skin GVHD and explore novel therapeutic treatment. Cytokines, such as interleukin (IL)-22, IL-17, IL-6 and interferon (IFN)-γ, have been proven to play pivotal roles in the progression of skin GVHD. Nevertheless, the specific mechanism remains elusive. In this article, research progresses at home and abroad on the mechanism underlying the roles of these cytokines in skin GVHD were reviewed, aiming to provide novel ideas for the prevention and treatment of skin GVHD.

3.
Journal of Leukemia & Lymphoma ; (12): 572-576, 2021.
Article in Chinese | WPRIM | ID: wpr-907217

ABSTRACT

Mantle cell lymphoma is a B-cell malignancy with unique biological, pathological and clinical characteristics, accounting for about 5%-10% of non-Hodgkin lymphoma (NHL), and most patients are diagnosed at advanced stage. Mantle cell lymphoma has the aggressive characteristic of aggressive lymphoma and the refractory characteristic of indolent lymphoma, and the prognosis of patients is poor. In recent years, with the development of high-dose chemotherapy, autologous hematopoietic stem cell transplantation and new drug research, the survival time of patients has been significantly prolonged.

4.
Journal of Leukemia & Lymphoma ; (12): 189-192, 2021.
Article in Chinese | WPRIM | ID: wpr-882261

ABSTRACT

Acute undifferentiated leukemia (AUL) is a clinically rare subtype of acute leukemia (AL). AUL lacks the serial specific antigen expressions, and the blasts have no morphological features of myeloid differentiation. Due to the rarity of AUL in clinic, there is no unified understanding of clinical and biological characteristics. It′s difficult to diagnose and choose the optimal treatment for AUL patients. And the prognosis of patients with AUL is poorer compared with other types of AL. Thanks to the big development of biotechnology in recent years, the related researchers have a better understanding of this rare disease. This article reviews the progress of diagnosis and treatment in AUL.

5.
Journal of Chinese Physician ; (12): 1433-1436, 2021.
Article in Chinese | WPRIM | ID: wpr-909718

ABSTRACT

Aplastic anemia(AA) is characterized by severe pancytopenia. The clinical features of bone marrow failure syndrome are closely related to viral infection, environment toxin, genetic and acquired gene mutation. Aplastic anemia is a historic disease that often occurred in young people, which was fatal to patients. However, here are many methods can treat and cure this fatal disease. Pathological and physiological studies have important guiding significance for the treatment of aplastic anemia. The diagnosis and treatment of current situation and prospect of aplastic anemia are reviewed in this article.

6.
Journal of Leukemia & Lymphoma ; (12): 505-508, 2020.
Article in Chinese | WPRIM | ID: wpr-862868

ABSTRACT

Multiple myeloma (MM) is a clonal proliferation of abnormal plasma cells. Beginning with the use of proteasome inhibitor (PI), the treatment of MM has been significantly improved. Ixazomib is a new generation of PI, the clinical studies have shown that it has good efficacy and safety in frontline therapy, maintenance therapy and treatment of relapsed/refractory MM patients, mainly reflected in prolonging progression-free survival, low peripheral neurotoxicity and long-term medication without accumulated toxicity. This article reviews the mechanism of action, pharmacokinetics, clinical studies and adverse reactions of ixazomib, in order to provide references for the treatment of MM.

7.
Journal of Leukemia & Lymphoma ; (12): 307-309, 2020.
Article in Chinese | WPRIM | ID: wpr-862829

ABSTRACT

In 2016, the World Health Organization redefined double hit lymphoma and double expression lymphoma as high-grade lymphoma, a group lymphoma characterized by aggressive disease and poor prognosis. Double hit lymphoma and double expression lymphoma are related to the abnormal expressions of c-myc, bcl-2 and bcl-6 genes. Because of the differences in disease progression and prognosis of both lymphomas, R-CHOP is less effective in treating them. The adjusted R-Hyper-CVAD, R-CODOX-M/IVAC and R-EPOCH regimens have shown good results, but targeted therapy may be the most effective regimen due to their specific genetic abnormalities. This article will review its clinical characteristics, pathogenesis, diagnosis and treatment of double hit lymphoma and double expression lymphoma.

8.
Article in Chinese | WPRIM | ID: wpr-781438

ABSTRACT

Abstract  Langerhans cell histiocytosis (LCH) is a disease originated from bone marrow dendritic cells, and classified as a tumor by the discovery of a recurrent somatic BRAF-V600E point mutation in the RAS-RAF-MEK-ERK signaling pathway. The clinical manifestations of LCH are mainly granulomatous lesions composed of clonal pathological tissue cells. According to the lesions and invasive risk organs, it is divided into single system diseases, multi-system diseases with risk-free organ infiltration and multi-system diseases with risk organ infiltration. The diagnosis was based on immunohistochemical pathological dendritic cell-specific markers CD1α+and/or CD207,therefore, according to risk stratification, the regiment and intensity of combination chemotherapy and targeted therapy are drawn up. Prognosis is associates with risk organ infiltration, initial treatment response, and BRAF mutations. Due to the low incidence and lack of systematic knowledge, the clinical understanding of this disease is insufficient, thus the rates of misdiagnosis and therapeutic error are high. In this review, the pathogenesis, clinical manifestations, diagnostic and treatment are summarized. So on to provide a theroretical basis for clinical diagnosis and treatment of the diseases.

9.
Article in Chinese | WPRIM | ID: wpr-802677

ABSTRACT

Chronic lymphocytic leukemia(CLL) is a heterogeneous mature B lymphocytic tumor.The apoptosis of mature lymphocyte is inhibited and clonal proliferation of mature lymphocyte aggregates in blood, bone marrow, spleen and lymph nodes, resulting in a class of inert hematological tumors.At present, the clinical pathogenesis is not completely clear, environmental and occupational factors do not occupy a major position.Studies have shown that long-term exposure to low-frequency electromagnetic fields may be associated with its incidence, but patients with primary and secondary relatives of lymphatic malignancies increased incidence.Many families still have patients whose age is earlier and the disease is more serious.In recent years, with the continuous improvement of medical level, a variety of treatment methods for chronic lymphoblastic leukemia have emerged, including a variety of new drugs.Ibutinib is the world's first marketed Bruton's tyrosine kinase(BTK) inhibitor, for more patients with chronic lymphoblastic leukemia has brought the gospel.This article reviews the clinical research progress of ibrutinib in treating CLL.

10.
Journal of Leukemia & Lymphoma ; (12): 698-701, 2019.
Article in Chinese | WPRIM | ID: wpr-801617

ABSTRACT

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a kind of highly malignant tumor in the hematological system, which is characterized with low incidence, diverse clinical manifestations, strong invasiveness and poor prognosis, however, currently there has no standard treatment yet. This paper reviews the recent research progress of BPDCN.

11.
Journal of Leukemia & Lymphoma ; (12): 637-640, 2019.
Article in Chinese | WPRIM | ID: wpr-797220

ABSTRACT

Uroacitide is a new anti-tumor drug, which is extracted from non-cytotoxic urine of the healthy human urine. In recent years, there have been many basic experiments and clinical trials focusing on its role in hematological diseases, especially in the treatment of myelodysplastic syndromes (MDS). There are also some basic researches on the treatment of other hematological diseases, which lays a foundation for further expanding its clinical indications and opens up a new way for the treatment of hematological diseases.

12.
Article in Chinese | WPRIM | ID: wpr-753687

ABSTRACT

Chronic lymphocytic leukemia(CLL) is a heterogeneous mature B lymphocytic tumor.The apoptosis of mature lymphocyte is inhibited and clonal proliferation of mature lymphocyte aggregates in blood,bone marrow,spleen and lymph nodes,resulting in a class of inert hematological tumors.At present,the clinical pathogenesis is not completely clear,environmental and occupational factors do not occupy a major position. Studies have shown that long -term exposure to low-frequency electromagnetic fields may be associated with its incidence,but patients with primary and secondary relatives of lymphatic malignancies increased incidence. Many families still have patients whose age is earlier and the disease is more serious.In recent years,with the continuous improvement of medical level,a variety of treatment methods for chronic lymphoblastic leukemia have emerged,including a variety of new drugs.Ibutinib is the world's first marketed Bruton's tyrosine kinase(BTK) inhibitor,for more patients with chronic lymphoblastic leukemia has brought the gospel.This article reviews the clinical research progress of ibrutinib in treating CLL.

13.
Article in Chinese | WPRIM | ID: wpr-753578

ABSTRACT

Primary immune thrombocytopenia is an autoimmune disease characterized by reduced platelets, accompanied by or without skin mucous bruises,epistaxis,internal bleeding,etc.Recent years,the treatment of primary immune thrombocytopenia developed very quickly, including the appearance of platelet receptor agonist - Eltrom-bopag.Here,we reviewed the treatment and research development of primary immune thrombocytopenia.

14.
Article in Chinese | WPRIM | ID: wpr-733935

ABSTRACT

Primary immune thrombocytopenia is an autoimmune disease characterized by reduced platelets, accompanied by or without skin mucous bruises,epistaxis,internal bleeding,etc. Recent years,the treatment of primary immune thrombocytopenia developed very quickly, including the appearance of platelet receptor agonist - Eltrom-bopag. Here,we reviewed the treatment and research development of primary immune thrombocytopenia.

15.
Journal of Experimental Hematology ; (6): 1907-1911, 2019.
Article in Chinese | WPRIM | ID: wpr-781520

ABSTRACT

OBJECTIVE@#To explore the effects of different concentration of pomalidomide on human multiple myeloma cell line MM1.S and the expression of CRBN.@*METHODS@#CCK-8 method was used for detecting inhibition effect of promalidomide on proliferation of MM1.S cells. Apoptosis rate of MM1.S cells was detected by flow cytometry with Annexin V-FITC/PI double staining. Real-time quantitative PCR was used to determine CRBN gene expression level. Western blot was used to detect the effect of pomalidomide on the protein expression of CRBN in MM1.S cells.@*RESULTS@#Pomalidomide has an inhibitory effect on MM1.S cells with time-and dose-dependent manners. Pomalidomide induced apoptosis in MM1.S cells. When the concentration of pomalidomide was 0, 40 and 80 μmol/L, the expression of CRBN gene after the treatment of MM1.S cells for 72 hours was 1.487±0.340, 0.211±0.054 and 0.055±0.005, by using actin as internal refereme. Pomalidomide significantly reduced CRBN protein expression in MM1.S cells.@*CONCLUSION@#Pomalidomide can inhibit the proliferation of MM1.S cells and promote its apoptosis. A certain concentration of pomalidomide can reduce the expression of CRBN gene and down-regulate its protein expression in MM1.S cells.


Subject(s)
Adaptor Proteins, Signal Transducing , Apoptosis , Cell Line, Tumor , Cell Proliferation , Humans , Multiple Myeloma , Thalidomide
16.
Journal of Leukemia & Lymphoma ; (12): 637-640, 2019.
Article in Chinese | WPRIM | ID: wpr-789049

ABSTRACT

Uroacitide is a new anti-tumor drug, which is extracted from non-cytotoxic urine of the healthy human urine. In recent years, there have been many basic experiments and clinical trials focusing on its role in hematological diseases, especially in the treatment of myelodysplastic syndromes (MDS). There are also some basic researches on the treatment of other hematological diseases, which lays a foundation for further expanding its clinical indications and opens up a new way for the treatment of hematological diseases.

17.
Article in Chinese | WPRIM | ID: wpr-700344

ABSTRACT

Eltrombopag is a kind of human thrombopoietin receptor agonist, which is used to treat thrombocytopenia and severe aplastic anemia. In recent years, it highlights the huge advantage in iron removal. It regulates the acidification of glucuronidation in the body, removing it from feces and urine before iron conjugates to the liver, so as to effectively reduce the overload of iron in the body.

18.
Article in Chinese | WPRIM | ID: wpr-700225

ABSTRACT

Primary bone lymphoma(PBL)is rare and has no specific clinical features.A mouth-eaten pattern of bone destruction in metaphysic or subchondral bone and a large soft-tissue mass with little cortical destruction are important imaging features of primary bone lymphoma. The final diagnosis mainly depends on the histopathological features and the expression of specific proteins showing by immunohistochemical staining. It bears a good outcome after radiation and chemical therapy. The operation is not a routine therapy method.So, it is important to make accurate diagnosis before radiation and chemical therapy. In this article, we reviewed the clinical diagnosis, treatment, and prognosis of primary bone lymphoma.

19.
Article in Chinese | WPRIM | ID: wpr-700205

ABSTRACT

POEMS syndrome is a disease associated with plasma cell paraneoplastic syndrome. There is no unified standard treatment, and often general symptomatic treatment, drug treatment, radiotherapy, autologous hematopoietic stem cell transplantation, etc. is used. The latest treatment progress of POEMS syndrome is reviewed.

20.
Journal of Leukemia & Lymphoma ; (12): 636-640, 2018.
Article in Chinese | WPRIM | ID: wpr-691684

ABSTRACT

Cytarabine is an anti-metabolic drug with cytotoxicity, which plays an important role in the treatment of acute leukemia. Cytarabine mainly acts on S proliferation phase of tumor cells. Normally, cytosine integrates with deoxyribose to form deoxycytidine, which is one of the components of DNA. Cytarabine is a deoxycytidine analogue, which can replace the former to form DNA. Therefore, it inhibits the synthesis of cellular DNA, interferes with the proliferation of tumor cells and achieves the therapeutic purpose, due to the different structure. Different genetic backgrounds and different efficiencies of drug absorption, metabolism and elimination may result in changes in the effectiveness of the drug regimen containing cytarabine, which may affect the survival of patients with acute leukemia. The research progress of drug resistance mechanism of cytarabine in acute leukemia is reviewed and summarized in this paper.

SELECTION OF CITATIONS
SEARCH DETAIL